For-Sight Ophthalmics

For-Sight Ophthalmics is a specialized biotechnology company focused on developing innovative sustained-release drug delivery technologies for ocular health. A spin-out from the University of Birmingham, the company developed a proprietary hydrogel platform designed to deliver medication to the eye over extended periods, addressing the significant challenge of patient non-compliance with daily eye drops. The technology is particularly applicable to chronic conditions such as glaucoma and ocular hypertension. In 2017, the company was acquired by Santen Pharmaceutical, a global leader in ophthalmology, to integrate its delivery platform into Santen's therapeutic pipeline. This acquisition aimed to enhance the efficacy and convenience of treatments for sight-threatening diseases.